As of July 1 02:10 P.M., GemVax was at a bullish 7.47% compared with yesterday, to 15,100 won. It had declined 1.31% through the past month. GemVax is a Korean high-tech company.
Compared with its close competitors within the same industry, KOSDAQ, as the monthly volatility of GemVax remained at the highest level, the investment return for 1 month was negative.
Comparing industry to the market, the KOSDAQ industry including GemVax records lower volatility and earning rate than Machine·Equipment. In other words, the industry had less volatility and the returns were also smaller than the market.
Target price 25,000 won
Per analysts’ expectations during the recent month, the average target price of GemVax is 25,000 won. The stock price is 15,100 won as of yesterday, so there is 9,900 won (65%) disparate in order to be able to increase.
Institutions & Individuals buy, Foreigners sell
From June 24, Institutions have been continuously buying GemVax during the past 5 trading days.
As a shareholding sum by the investor group for the past 4 weeks, Institutions have bought 162,511 shares as they turn toward a buying stance and Individuals have bought 170,866 shares lessening its position.
However, during the same period, Foreigners have sold 83,734 shares with the maintenance of a selling position.
Regarding the statistics for the past month on trade volume as the total outstanding shares, the daily turnover rate of GemVax was 0.6%. The daily volatility during the same period is 8.66%, so the range of rise and fall has been high.
As per the inquiry for shareholding by the investor group, the major investor group is Individuals with 68.38% from total outstanding shares. Foreigners and Institutions each hold 14.46% and 13.39%.
And as recent 5-day shareholding change by the investor group, Individuals is the major investor group with 72.13%. Institutions hold 13.96% and Foreigners hold 13.03%.
(Editorial Note) This article is provided by ThinkPool, a Korean artificial intelligence developer. Its AI algorithm automatically produced this article, which is edited with Google Grammarly. If there are any issues or if readers have any comments, please contact email@example.com or 82-2-6956-6698.